5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Seizure O
occurred O
in O
0.5 O
% O
of O
patients O
receiving O
XTANDI O
. O

In O
patients O
with O
predisposing O
factors O
, O
seizures O
were O
reported O
in O
2.2 O
% O
of O
patients O
. O

Permanently O
discontinue O
XTANDI O
in O
patients O
who O
develop O
a O
seizure O
during O
treatment O
. O

( O
5.1 O
) O
* O
Posterior O
reversible O
encephalopathy O
syndrome O
( O
PRES O
) O
: O
Discontinue O
XTANDI O
. O

( O
5.2 O
) O
5.1 O
Seizure O
Seizure B-OSE_Labeled_AE
occurred O
in O
0.5 O
% O
of O
patients O
receiving O
XTANDI O
in O
clinical O
studies O
. O

In O
these O
trials O
patients O
with O
predisposing O
factors O
for O
seizure B-NonOSE_AE
were O
generally O
excluded O
. O

Seizure B-OSE_Labeled_AE
occurred O
from O
31 O
to O
603 O
days O
after O
initiation O
of O
XTANDI O
. O

Patients O
experiencing O
seizure B-NonOSE_AE
were O
permanently O
discontinued O
from O
therapy O
and O
all O
seizure B-NonOSE_AE
events O
resolved O
. O

In O
a O
single-arm O
trial O
designed O
to O
assess O
the O
risk O
of O
seizure B-NonOSE_AE
in O
patients O
with O
pre-disposing O
factors O
for O
seizure B-NonOSE_AE
, O
8 O
of O
366 O
( O
2.2 O
% O
) O
XTANDI-treated O
patients O
experienced O
a O
seizure B-OSE_Labeled_AE
. O

Three O
of O
the O
8 O
patients O
experienced O
a O
second O
seizure B-OSE_Labeled_AE
during O
continued O
treatment O
with O
XTANDI O
after O
their O
first O
seizure B-NonOSE_AE
resolved O
. O

It O
is O
unknown O
whether O
anti-epileptic O
medications O
will O
prevent O
seizures B-NonOSE_AE
with O
XTANDI O
. O

Patients O
in O
the O
study O
had O
one O
or O
more O
of O
the O
following O
pre-disposing O
factors O
: O
the O
use O
of O
medications O
that O
may O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
( O
~ O
54 O
% O
) O
, O
history O
of O
traumatic B-Not_AE_Candidate
brain I-Not_AE_Candidate
or I-Not_AE_Candidate
head I-Not_AE_Candidate
injury I-Not_AE_Candidate
( O
~ O
28 O
% O
) O
, O
history O
of O
cerebrovascular B-Not_AE_Candidate
accident I-Not_AE_Candidate
or O
transient B-Not_AE_Candidate
ischemic I-Not_AE_Candidate
attack I-Not_AE_Candidate
( O
~ O
24 O
% O
) O
, O
and O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
meningioma B-Not_AE_Candidate
, O
or O
leptomeningeal B-Not_AE_Candidate
disease I-Not_AE_Candidate
from O
prostate B-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
unexplained O
loss B-Not_AE_Candidate
of I-Not_AE_Candidate
consciousness I-Not_AE_Candidate
within O
the O
last O
12 O
months O
, O
past O
history O
of O
seizure B-Not_AE_Candidate
, O
presence O
of O
a O
space B-Not_AE_Candidate
occupying I-Not_AE_Candidate
lesion I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
brain I-Not_AE_Candidate
, O
history O
of O
arteriovenous B-Not_AE_Candidate
malformation I-Not_AE_Candidate
, O
or O
history O
of O
brain B-Not_AE_Candidate
infection I-Not_AE_Candidate
( O
all O
< O
5 O
% O
) O
. O

Approximately O
17 O
% O
of O
patients O
had O
more O
than O
one O
risk O
factor O
. O

Advise O
patients O
of O
the O
risk O
of O
developing O
a O
seizure B-NonOSE_AE
while O
receiving O
XTANDI O
and O
of O
engaging O
in O
any O
activity O
where O
sudden O
loss B-NonOSE_AE
of I-NonOSE_AE
consciousness I-NonOSE_AE
could O
cause O
serious O
harm O
to O
themselves O
or O
others O
. O

Permanently O
discontinue O
XTANDI O
in O
patients O
who O
develop O
a O
seizure B-NonOSE_AE
during O
treatment O
. O

5.2 O
Posterior O
Reversible O
Encephalopathy O
Syndrome O
( O
PRES O
) O
There O
have O
been O
reports O
of O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
in O
patients O
receiving O
XTANDI O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

PRES B-NonOSE_AE
is O
a O
neurological B-NonOSE_AE
disorder I-NonOSE_AE
which O
can O
present O
with O
rapidly O
evolving O
symptoms O
including O
seizure B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
blindness B-NonOSE_AE
, O
and O
other O
visual B-NonOSE_AE
and O
neurological O
disturbances I-NonOSE_AE
, O
with O
or O
without O
associated O
hypertension B-NonOSE_AE
. O

A O
diagnosis O
of O
PRES B-NonOSE_AE
requires O
confirmation O
by O
brain O
imaging O
, O
preferably O
magnetic O
resonance O
imaging O
( O
MRI O
) O
. O

Discontinue O
XTANDI O
in O
patients O
who O
develop O
PRES B-NonOSE_AE
. O

